NCT03624543 is a Phase 2 clinical trial of CFI-400945 in Breast Cancer, sponsored by Canadian Cancer Trials Group.

Who is sponsoring NCT03624543?

NCT03624543 is sponsored by Canadian Cancer Trials Group.

What drugs are being tested in NCT03624543?

Interventions in NCT03624543: CFI-400945.

What condition does NCT03624543 study?

NCT03624543 studies Breast Cancer.

Is NCT03624543 still recruiting?

NCT03624543 is currently active, enrolled. Last updated 30 January 2026.

Last reviewed 2026-01-30 · How we verify

NCT03624543

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

Active, enrolled Phase 2 Last updated 30 January 2026

What this trial tests

Phase 2 trial testing CFI-400945 in Breast Cancer in 51 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

14 February 2019

Primary endpoint
30 June 2026

31 December 2026

Quick facts

Lead sponsor	Canadian Cancer Trials Group
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	51
Start date	14 February 2019
Primary completion	30 June 2026
Estimated completion	31 December 2026
Sites	6 locations across Canada

Drugs / interventions tested

CFI-400945 — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Canadian Cancer Trials Group — full company profile →

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The standard or usual treatment for this disease is to undergo chemotherapy to slow the spread of the disease and relieve some symptoms of cancer. Patients will have already had at least one chemotherapy treatment for their disease at this stage.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

PLK4: a promising target for cancer therapy.
Zhao Y, Wang X, Wang X. · · 2019 · cited 55× · PMID 31492983 · DOI 10.1007/s00432-019-02994-0
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial.
Veitch ZW, Cescon DW, Denny T, Yonemoto LM, et al · · 2019 · cited 46× · PMID 31303643 · DOI 10.1038/s41416-019-0517-3
Polo-Like Kinase 4's Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy.
Zhang X, Wei C, Liang H, Han L. · · 2021 · cited 44× · PMID 33777739 · DOI 10.3389/fonc.2021.587554
Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer.
Suri A, Bailey AW, Tavares MT, Gunosewoyo H, et al · · 2019 · cited 33× · PMID 31035676 · DOI 10.3390/ijms20092112
CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer.
Zhong C, Jiang WJ, Yao Y, Li Z, et al · · 2024 · cited 30× · PMID 38951519 · DOI 10.1038/s41467-024-49673-4
Harnessing the cyclization strategy for new drug discovery.
Tang K, Wang S, Gao W, Song Y, et al · · 2022 · cited 29× · PMID 36562004 · DOI 10.1016/j.apsb.2022.09.022
Role of Polo-Like Kinase 4 (PLK4) in Epithelial Cancers and Recent Progress in its Small Molecule Targeting for Cancer Management.
Garvey DR, Chhabra G, Ndiaye MA, Ahmad N. · · 2021 · cited 27× · PMID 33402398 · DOI 10.1158/1535-7163.mct-20-0741
Seize the engine: Emerging cell cycle targets in breast cancer.
Fuentes-Antrás J, Bedard PL, Cescon DW. · · 2024 · cited 21× · PMID 38264947 · DOI 10.1002/ctm2.1544

Verify or expand the search:

Other trials of CFI-400945

Trials testing the same drug.

NCT05601440 — Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer · Phase 2 · recruiting
NCT04176848 — CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer · Phase 2 · active not recruiting
NCT03385655 — Prostate Cancer Biomarker Enrichment and Treatment Selection · Phase 2 · active not recruiting

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Canadian Cancer Trials Group trials

Trials by the same sponsor.

NCT07390435 — Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials · not yet recruiting
NCT07297667 — GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours · Phase 1 · not yet recruiting
NCT06630273 — Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated With Immuno-Oncotherape · not yet recruiting
NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07341191 — Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03624543 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Canadian Cancer Trials Group
Last refreshed: 30 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03624543.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing